VYXEOS for Secondary AML | Common Sense Oncology Journal Club

Join Drs. Aaron Goodman, Bernard Marini, and Manju Sengar of the Common Sense Oncology movement as they discuss CPX-351 (Vyxeos) in the Treatment of Secondary AML. Introduction of Speakers - 0:44 Introduction of CSO - 1:10 Background - 5:08 What is CPX-351 (Vyxeos)? - 14:55 Questions to ask before reading clinical trial results - 17:00 CPX-351 Phase III Trial Results - 20:23 Trial Outcome - 26:18 Critical Appraisal - 27:08 Wrapping up//Q&A - 48:50